Skip to main content
Adaptimmune Therapeutics plc (ADAP)
NASDAQ: ADAP · Real-Time Price · USD
0.605
+0.005 (0.82%)
At close: Dec 20, 2024, 4:00 PM
0.592
-0.013 (-2.12%)
After-hours: Dec 20, 2024, 5:03 PM EST

Adaptimmune Therapeutics Revenue

Adaptimmune Therapeutics had revenue of $40.90M in the quarter ending September 30, 2024, with 458.83% growth. This brings the company's revenue in the last twelve months to $175.04M, up 146.27% year-over-year. In the year 2023, Adaptimmune Therapeutics had annual revenue of $60.28M with 122.05% growth.

Revenue (ttm)
$175.04M
Revenue Growth
+146.27%
P/S Ratio
0.85
Revenue / Employee
$389,846
Employees
449
Market Cap
154.78M

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 202360.28M33.13M122.05%
Dec 31, 202227.15M21.00M341.50%
Dec 31, 20216.15M2.19M55.36%
Dec 31, 20203.96M2.84M252.76%
Dec 31, 20191.12M-58.38M-98.11%
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro
Dec 31, 2015 Pro Pro Pro
Jun 30, 2015 Pro Pro Pro
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Sutro Biopharma 160.96M
Seres Therapeutics 126.33M
The Joint 120.80M
Metagenomi 55.08M
Nanobiotix 45.22M
Cellectis 36.04M
Revenue Rankings

ADAP News

More News